News in other languages: HANDOK Inc.

27/07/23

Hogere omzet en kleiner verlies voor Argenx

Managers and Directors: HANDOK Inc.

Manager	Title	Age	Since
Jin-Ki Baik CEO	Chief Executive Officer	69	-
Young-Jin Kim CEO	Chief Executive Officer	68	31/12/1995
Hyeon-Cheol Lee DFI	Director of Finance/CFO	58	-

Director	Title	Age	Since
Young-Jin Kim CHM	Chairman	68	31/12/1995
Jin-Ki Baik BRD	Director/Board Member	69	-
Young Kim BRD	Director/Board Member	58	-

More insiders

Handok Inc is a Korea-based company primarily engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through four segments. The Pharmaceutical segment mainly manufactures and sells prescription and over-the-counter drugs, including treatments for diabetes, hypertension, kidney diseases, respiratory diseases, central nervous system disorders, rare diseases, as well as anticancer drugs. The Medical Device segment mainly sells medical devices and diagnostic reagents. The Contract Manufacturing segment mainly provides contract manufacturing and quality control services for pharmaceuticals. The Real Estate Leasing segment mainly engages in the real estate leasing business.

Employees

910

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	₩8,370.00	+2.57%	1,751
15/10/26	₩8,160.00	-1.81%	7,076
14/10/26	₩8,310.00	+1.84%	4,885
13/10/26	₩8,160.00	-1.57%	3,503
12/10/26	₩8,290.00	-3.60%	2,311

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 16/10/2026			5-day change	1st Jan Change
8,370.00 ^KRW	+2.57%		-2.67%	-25.27%

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-10	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI

Market Cap	109B 81.56M 72.5M 67.19M 61.14M 115M 7.74B 117M 808M 317M 4.04B 306M 300M 12.88B	P/E 2024	-3.16x	P/E 2025	-69x
Enterprise Value	459B 344M 306M 284M 258M 487M 32.69B 495M 3.41B 1.34B 17.06B 1.29B 1.27B 54.38B	EV / Sales 2024	0.95x	EV / Sales 2025	0.93x
Free-Float	52.22%	Yield 2024	1.66%	Yield 2025	-

04-30	Handok Q1 operating profit 207 million won, swings to profit from year earlier	RE
02-10	HANDOK Inc. announces Annual dividend, payable on April 24, 2026	CI
02-10	Handok Q4 operating profit 4.2 billion won, swings to profit from year earlier	RE
30/10/25	Handok Q3 operating profit 287 million won, swings to profit from year earlier	RE
10/09/25	Teva Handok Announces UZEDY Receives Regulatory Approval from the South Korean Ministry of Food and Drug Safety	CI
12/05/25	Handok To Divest 9 Billion Won Worth Of Own Shares	RE
30/04/25	Handok Q1 Operating Loss 1.6 Billion Won	RE
05/02/25	Handok Q4 Operating Loss 2.7 Billion Won	RE
08/12/24	HANDOK Inc. announced that it expects to receive KRW 30 billion in funding	CI
25/06/24	WELT Corp., Ltd announced that it has received KRW 14 billion in funding from Envisioning Partners, Korea Development Bank, Investment Arm, Shinhan Venture Investment Co, Ltd., IMM Investment, Corp., HANDOK Inc.	CI
24/05/24	Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea	MT
24/05/24	Biocon Limited Signs Exclusive Licensing and Supply Deal for the Commercialization of Liraglutide in South Korea with Handok Inc	CI
16/04/24	Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	MT

14/02/24	Sobi and Handok establish joint venture for rare disease business in South Korea	AQ
03/04/17	Handok : Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Trial with long-acting growth hormone, GX-H9 at ENDO 2017	BU

HANDOK Inc. Share Price

Stocks

A002390

KR7002390003

Pharmaceuticals

Valuation: HANDOK Inc.

Chart: HANDOK Inc.

Latest news: HANDOK Inc.

Press Releases: HANDOK Inc.

News in other languages: HANDOK Inc.

Quotes and Performance

Price Extremes

Managers and Directors: HANDOK Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	+2.57%
1 week	-2.67%
Current month	-0.71%
1 month	-0.95%
3 months	-0.36%
6 months	-21.85%
Current year	-25.27%

1 week	7,970	8,600
1 month	7,970	9,360
Current year	6,460	11,820
1 year	6,460	12,150
3 years	6,460	20,300
5 years	6,460	24,800
10 years	6,460	44,750

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HANDOK INC.	+2.57%	-2.67%	-27.97%	-32.50%	81.56M
ELI LILLY AND COMPANY	+0.43%	+6.59%	+56.57%	+106.64%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+32.26%	+63.73%	616B
ABBVIE INC.	+0.71%	+3.24%	+24.33%	+91.33%	504B
ROCHE HOLDING AG	-0.13%	+5.98%	+33.66%	+50.18%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+72.13%	+40.11%	360B
NOVARTIS AG	-0.95%	+4.70%	+19.65%	+42.71%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.89%	+10.43%	258B
AMGEN INC.	-0.35%	+4.25%	+44.74%	+52.06%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+27.18%	+94.07%	194B
Average	+0.10%	+3.35%	+28.17%	+51.88%	394.1B
Weighted average by Cap.	+0.13%	+3.83%	+39.33%	+71.82%

	2024	2025
Net sales	507B 381M 338M 314M 285M 538M 36.12B 547M 3.77B 1.48B 18.85B 1.43B 1.4B 60.08B	535B 401M 357M 331M 301M 568M 38.09B 577M 3.98B 1.56B 19.88B 1.51B 1.47B 63.37B
Net income	-52.56B -39.43M -35.05M -32.48M -29.55M -55.77M -3.74B -56.66M -390M -153M -1.95B -148M -145M -6.22B	-2.15B -1.61M -1.44M -1.33M -1.21M -2.28M -153M -2.32M -15.99M -6.27M -79.98M -6.06M -5.93M -255M
Net Debt	317B 238M 212M 196M 178M 337M 22.59B 342M 2.36B 924M 11.79B 893M 874M 37.58B	351B 263M 234M 217M 197M 372M 24.95B 378M 2.6B 1.02B 13.02B 987M 966M 41.51B